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Abstract: Membrane type-1 matrix metalloproteinase (MT1-MMP or MMP-14) plays an 
important role in adverse cardiac remodelling. Here, we aimed to develop radiolabeled 
activatable cell penetrating peptides (ACPP) sensitive to MT1-MMP for the detection of 
elevated MT1-MMP levels in adverse cardiac remodelling. Three ACPP analogs were 
synthesized and the most potent ACPP analog was selected using MT1-MMP sensitivity and 
enzyme specificity assays. This ACPP, called ACPP-B, showed high sensitivity towards 
MT1-MMP, soluble MMP-2, and MT2-MMP, while limited sensitivity was measured for 
other members of the MMP family. In in vitro cell assays, radiolabeled ACPP-B showed 
efficient cellular uptake upon activation. A pilot in vivo study showed increased uptake of 
the radiolabeled probe in regions of infarcted myocardium compared to remote myocardium, 
warranting further in vivo evaluation. 
Keywords: molecular imaging; activatable cell penetrating peptide; matrix 
metalloproteinase-14; membrane type-1 matrix metalloproteinase; radiolabeling; 
myocardial infarction; peptide chemistry 
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1. Introduction 
The use of activatable cell penetrating imaging probes is a promising strategy for the in vivo detection 
of proteolytic activity in pathological conditions [1–3]. A radiolabeled activatable cell penetrating 
peptide (ACPP) sensitive toward matrix metalloproteinases (MMP)-2 and -9 was successfully employed 
for MMP detection in the course of remodeling post-myocardial infarction in vivo [1]. Besides activation 
in infarcted heart tissue, the MMP-2/9 sensitive ACPP probe also showed a considerable degree of 
activation in the vascular compartment, leading to background uptake of the activated probe in basically 
all tissues [1]. Therefore, the development of ACPPs which are only activated in the tissue of interest by 
tissue-specific enzymes should be the next step in optimization of the elegant ACPP concept. Membrane 
type-1 matrix metalloproteinase (MT1-MMP or MMP-14) has been identified to be such a tissue-specific 
target. MT1-MMP is involved in several protein modification and biological signaling pathways [4,5]. 
Specifically, MT1-MMP has been shown to convert the pro-enzyme MMP-2 into its active form, thereby 
facilitating extracellular matrix proteolysis [5,6]. Furthermore, MT1-MMP has been recognized as 
playing an important role in the profibrotic cascade by activation of the transforming growth factor-beta 
(TGF) pathway and subsequent induction of fibrillar collagens [5,6]. As such, MT1-MMP is involved 
in a variety of physiological, but also pathological tissue remodeling processes. For example in cancer,  
MT1-MMP plays a significant role in tumor growth and metastasis [7–9]. In atherosclerosis, MT1-MMP 
is directly linked to pathogenesis of plaque vulnerability [10]. Furthermore, MT1-MMP expression and 
activity is increased in pressure overload hypertrophy and in left-ventricular remodelling after cardiac 
ischemia-reperfusion injury or myocardial infarction, contributing to cardiac dysfunction [5,11–14]. In 
this respect, MT1-MMP upregulation holds great promise as an early biomarker for a variety of diseases. 
Several groups have reported on the development and/or application of MT1-MMP molecular imaging 
probes. MT1-MMP probes based on binding to the active site used peptide ligands or antibodies and 
were applied in near infrared fluorescence imaging, magnetic resonance imaging, or SPECT  
imaging [15–18]. Furthermore, MT1-MMP activatable molecular imaging probes have been developed 
for near infrared fluorescence imaging and SPECT imaging. Spinale and coworkers used an MT1-MMP 
specific fluorogenic substrate for MT1-MMP detection following cardiac ischemia-reperfusion injury [5,11]. 
Ouyang et al., developed a genetically encoded fluorescence resonance energy transfer (FRET) imaging 
probe by flanking the MT1-MMP cleavage domain in the pro-peptide sequence of MMP-2 by the 
fluorescent proteins ECFP and YPet [19]. This genetically encoded biosensor was further optimized by 
employing an MT1-MMP substrate, CRPAH-LRDSG, with enhanced sensitivity for MT1-MMP [20]. 
Watkins et al., investigated the use of an MT1-MMP ACPP for SPECT-imaging by inserting the  
MT1-MMP peptide substrate SGRIGF-LRTA between a radiolabeled polycationic and polyanionic 
peptide domain [21,22]. In this approach, in vitro activation was observed in cell cultures expressing 
MT1-MMP, but a control cell line lacking MT1-MMP expression also activated the probe, and therefore 
MT1-MMP selectivity could not be demonstrated. In vivo studies for this latter probe have not been 
reported. In a recent study, the similar substrate GRIGF-LRTA was demonstrated to possess high 
sensitivity for MT1-MMP, but also for MT2-MPP and MT3-MMP, while the sensitivity towards MMP-2 
and MMP-9 was low [23]. By flanking the substrate with a Cy-5.5 fluorescent dye and a BHQ-3 
quencher an organic FRET imaging probe was obtained, which was successfully used for the in vivo 
detection of membrane-type matrix metalloproteinase activity by optical imaging [23]. 
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Here, we aimed to develop novel radiolabeled MT1-MMP ACPPs by using three MT1-MMP 
substrates different from the study of Watkins and colleagues (Figure 1). These substrates include the 
MT1-MMP cleavage domain in the pro-peptide sequence of MMP-2, CPKESCN-LFVLKD and the more 
MT1-MMP sensitive CRPAH-LRDSG substrate [19,20]. Furthermore, the peptide PLA-CmobWAR, which 
has been successfully used in an organic FRET probe for the monitoring of MT1-MMP in heart disease, 
was employed as MT1-MMP-selective sequence [12]. The polycationic and polyanionic domains 
consisted of D-amino acids to avoid proteolytic degradation of these domains. The cell penetrating 
peptide domain of the ACPPs was functionalized with a DOTA chelate to enable radiolabeling with 
177Lu. A dual-isotope radiolabeled MMP-2/9 ACPP (previously named dACPP, in this paper referred to 
as ACPP-2/9) approach recently proved valuable in the discrimination between intact and activated 
probe in in vivo biodistribution studies in mouse models of cancer and myocardial infarction [1,24,25]. 
Accordingly, we set out to develop dual-isotope radiolabeled MT1-MMP sensitive ACPPs using the 
orthogonal radio-isotopes 177Lu and 125I (Figure 1). To introduce the radiolabel 125I in the polyanionic 
inhibitory domain, either a tyrosine was introduced in the polyanionic inhibitory domain for direct 
radiolabeling, or 125I was introduced specifically to the N-terminus via coupling of a 125I labelled  
3-(4-hydroxyphenyl)propionic acid (SHPP) residue. The probes (ACPP-A, -B, and -C) were synthesized 
and studied for their MT1-MMP sensitivity and specificity. The best performing probe was subsequently 
studied in vivo in a pilot study in a mouse model of myocardial infarction and compared to ACPP-2/9. 
 
Figure 1. Mechanism and structure of proposed radiolabeled MT1-MMP activatable ACPPs. 
(A) The cell penetrating property of a polycationic peptide (in blue) is masked by a 
polyanionic peptide (in red). Cleavage of the substrate (in green) by MT1-MMP releases the 
polycationic cell penetrating peptide, which will transfer the radio-isotope 177Lu across the 
cell membrane, while the polyanionic domain together with the radioisotope 125I will be 
cleared from the tissue; (B) Peptide sequences of the three different MT1-MMP ACPP 
probes. The arrows indicate the MT1-MMP cleavage sites. In ACPP-A, the two cysteine 
residues form an intramolecular disulfide bridge. X and SHPP represent 3-oxapentanoic acid 
(O1Pen) and 3-(4-hydroxyphenyl)propionic acid, respectively. Design considerations for 
ACPP-C can be found in the supplementary information. The molecular structures of the 
different probes are presented in Figure S1. 
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2. Results and Discussion 
2.1. Probe Synthesis 
The peptides ACPP-A, ACPP-B, and ACPP-C with and without SHPP functionality were successfully 
prepared by Fmoc solid-phase peptide synthesis and in-solution coupling strategies, and purified by 
reversed phase—HPLC. Liquid chromatography—mass spectrometry (LC-MS) analysis demonstrated 
>95% pure peptides with molecular masses consistent with their theoretic masses (Figure 2). 
 
Figure 2. LC-MS characterization of (A) Ac-y-e9-X-C*PKESC*NLFVLKD-X-r9-dab(DOTA)-
NH2 (ACPP-A, obsd. 4951.4 Da, calcd. 4951.4 Da); (B) Ac-y-e9-X-CRPAHLRDSG-X-r9-
k(DOTA)-NH2 (ACPP-B, obsd. 4597.3 Da, calcd. 4597.3 Da), and (C) SHPP-e9-X-
PLACmobWAR-X-r8-k(DOTA)-NH2 (ACPP-C, obsd. 4209.1 Da, calcd. 4209.1 Da). C* 
represents cysteine residues that are linked via an intramolecular disulfide bridge. The left 
and right graphs show the UV absorbance chromatogram and the mass spectrum of the  
UV-peak bracketed by the arrowheads, respectively.  
2.2. MT1-MMP Sensitivity of ACPP Probes 
The peptides ACPP-A, ACPP-B, and ACPP-C (without SHPP functionality) were screened for  
MT1-MMP sensitivity by incubating the peptides (0.1 mM) with MT1-MMP (0.13 µM) for 60 min. For 
ACPP-A, a small fraction (<5%) of the peptide was cleaved between the asparagine and leucine residue 
(Figure 3A). In contrast, ACPP-B and ACPP-C were efficiently cleaved by MT1-MMP (Figure 3B,C). 
ACPP-A analogs (a peptide probe lacking the 5-amino-3-oxapentanoic acid linker residues and its linear 
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analog) were also synthesized and tested for MT1-MMP sensitivity, showing also a low degree of 
activation (Figure S2). Accordingly, a recent study found a poor response of a genetically encoded  
MT1-MMP biosensor employing the same substrate [20]. The low sensitivity of ACPP-A for MT1-MMP 
and the fact that ACPPs are expected to be cleared from the circulation relatively fast (blood half-life 
times of <30 min) [24], does not hold much promise for significant accumulation of ACPP-A in  
MT1-MMP expressing tissue, precluding in vivo imaging of MT1-MMP with this particular probe. 
Therefore, further in-depth analysis of the MT1-MMP specificity and in vivo characteristics of ACPP-A 
was not performed. 
 
Figure 3. LC-MS characterization of ACPP-A, ACPP-B, and ACPP-C (0.1 mM) incubated 
with MT1-MMP (0.13 µM) for 60 min. The left and right graphs show the UV absorbance 
chromatogram and the mass spectra of the UV-peaks bracketed by the arrowheads, 
respectively. (A) ACPP-A; MS spectra of Neutralizing domain (obsd. 2244.8 Da, calcd. 
2244.8 Da for Ac-y-e9-X-C*PKESC*N-COOH), and CPP (obsd. 2724.7 Da, calcd. 2724.7 
Da for H2N-LFVLKD-X-r9-dab(DOTA)-NH2). (B) ACPP-B; MS spectra of CPP (obsd. 
2565.5 Da, calcd. 2565.5 Da for H2N-LRDSG-X-r9-k(DOTA)-NH2), and Neutralizing 
domain (obsd. 2049.8 Da, calcd. 2049.8 Da for Ac-y-e9-X-CRPAH-COOH). (C) ACPP-C 
(without SHPP functionality); MS spectra of Neutralizing domain (obsd. 1561.5 Da,  
calcd. 1561.5 Da for e9-x-PLA-COOH), and CPP (obsd. 2517.4 Da, calcd. 2517.4 Da for 
H2N-CmobWAR-X-r8-k(DOTA)-NH2). C* represents cysteine residues that are linked via an 
intramolecular disulfide bridge. 
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2.3. Enzyme Specificity of ACPP-B & ACPP-C 
ACPP-B and ACPP-C were incubated with twelve different enzymes, including the soluble matrix 
metalloproteinases MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9, and the catalytic domains of  
MT1-MMP, MT2-MMP, and MT3-MMP (Figure 4). The sensitivity of the probes was also tested for 
the catalytic domain of ADAM-17, a desintegrin and metalloproteinase that is upregulated in heart 
failure. Finally, the sensitivity was determined towards enzymes present in the circulation, i.e., urokinase, 
plasmin, and thrombin. LC-MS analysis after 1 h of incubation showed that ACPP-B is efficiently 
cleaved between the histidine and leucine residue by MMP-2, MT1-MMP, and MT3-MMP. The other 
members of the MMP family effected minor degradation of ACPP-B, while negligible cleavage was 
observed for ADAM-17 and no cleavage was observed for thrombin, plasmin, and urokinase  
(Figure 4A). 
ACPP-C was efficiently cleaved, between the alanine and Cmob residue, by MMP-1, -7, MT1-MMP, 
MT2-MMP, and MT3-MMP, and to a modest extent by MMP-2, -3, and -9, while no ACPP-C cleavage 
was observed for ADAM-17, thrombin, plasmin, and urokinase (Figure 4B). Because MT1-MMP 
specificity was reported for the substrate PLACmobWAR flanked by two fluorophores, we were surprised 
to observe efficient cleavage of ACPP-C by other MMPs [11]. Attachment of the relatively large and 
charged peptide domains may have adversely affected the cleavage rate for MT1-MMP in competition 
with other MMPs. Due to the broad MMP sensitivity for both tissue-specific and soluble MMPs, ACPP-C is 
most likely also activated in the vascular compartment, and, as a result, represents at best only a marginal 
improvement compared to the ACPP-2/9 with respect to the specific targeting of proteolytic activity 
involved in myocardial remodeling [1]. ACPP-B was selected for further in vitro and in vivo analysis as 
it showed the most MT-MMP specificity. 
 
Figure 4. The percentage of released CPP from (A) ACPP-B and (B) ACPP-C (0.1 mM) 
after 1 h incubation with 12 different enzymes (20 nM) in vitro. The experiments were 
performed in triplicate and the data are presented as mean ± SD. Note: ACPP-C was 
incubated with 67 nM MMP-7 instead of 20 nM.  
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2.4. In Vitro Cell Assay ACPP-B 
Next, we radiolabeled the polycationic domain of ACPP-B with 177Lu (Figure S3) and set out to assess 
the uptake of 177Lu-ACPP-B by MMP-positive HT-1080 cells. Although these cells secrete MMPs, 
including MT1-MMP [26], it has been demonstrated that absolute enzyme levels are relatively low in  
2-dimensional cell culture experiments, resulting in minimal ACPP probe activation and insignificant 
uptake [27]. Therefore, we employed the same approach as previously reported for ACPP-2/9 [24,27]. 
That means, the cellular uptake was compared between radiolabeled pre-cleaved 177Lu-ACPP-B  
(>95% cleavage, Figure S3), uncleaved 177Lu-ACPP-B, a negative control and a positive control.  
177Lu-non-ACPP [24], which showed no MT1-MMP sensitivity, and 177Lu-CPP-B served as negative and 
positive control, respectively. CPP-B was obtained by MT1-MMP-mediated cleavage of ACPP-B and 
subsequent isolation of the polycationic domain by reversed phase-HPLC. After 3 h incubation at 1.25 µM, 
the cellular uptake of the activated 177Lu-ACPP-B was comparable to uptake of the positive control 
177Lu-CPP-B, and furthermore significantly higher with respect to uncleaved 177Lu-ACPP-B, and  
177Lu-non-ACPP (Figure 5), demonstrating efficient silencing of the CPP activity before probe 
activation. The concentration of 1.25 µM was four-fold lower compared to the intermolecular Km 
between the polyanionic and polycationic domain [27]. As such, pre-cleavage of ACPP-B was expected 
to result in efficient dissociation of the polyanionic and polycationic domain, leaving the activated CPP 
free for cellular adhesion and subsequent uptake. 
 
Figure 5. Cellular uptake of 177Lu-non-ACPP, uncleaved 177Lu-ACPP-B, pre-activated 
177Lu-ACPP-B, and 177Lu-CPP-B after 3h incubation with HT-1080 cells, assessed by  
γ-counting. Data are presented as mean ± SD. 
Although not significant, intact 177Lu-ACPP-B exhibited a slightly higher uptake and retention 
compared to the negative control 177Lu-non-ACPP (Figure 5), while this was not observed for a  
MMP-2/9 sensitive 177Lu-ACPP [24]. We continued to investigate if the modest uptake of intact  
ACPP-B was possibly mediated through activation by membrane-type MT1-MMP and MT3-MMP 
expressed by HT-1080 cells [26]. Thereto, the negative control, intact ACPP-B, and pre-cleaved  
ACPP-B were incubated with HT-1080 cells in the presence of a broad-spectrum MMP inhibitor, 
GM6001. The presence of GM6001 did not affect the cellular uptake of ACPP-B (Figure S4), and this 
suggests that MT-MMP mediated activation did not play a role and that the difference in cellular uptake 
between ACPP-B and the negative control is most likely caused by differences in probe structure. In 
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these experiments, we used the scrambled negative control for the MMP-2/9 ACPP [24] that also showed no 
MT1-MMP sensitivity. However, the linkers for ACPP-B and non-ACPP, O1Pen-CRPAHLRDSG-O1Pen 
and Ahx-LALGPG respectively, are rather different. A major dissimilarity is that the linker of non-ACPP 
consists solely of hydrophobic, non-polar amino acids, while the linker of ACPP-B mainly contains polar 
amino acids. It might be that the linker of ACPP-B can interact with proteins/cells via hydrogen bonding 
mediating some cellular retention. Another difference is that the linker of ACPP-B consists of 42 bonds 
versus 25 bonds for the linker in non-ACPP. Therefore, the effective molarity (EM) [27,28] for ACPP-B, 
23 mM, is lower compared to non-ACPP, 49 mM, and may lead to a higher level of dissociation of the 
polycationic and polyanionic domain and thus less efficient masking of the cell penetrating property of 
the polycationic peptide in ACPP-B. Yet, efficient intramolecular hairpin formation and subsequent 
masking of the cell penetrating property is expected for both probes as the EMs are much higher than 
the 5.9 µM intermolecular affinity between the polycationic and polyanionic domain [27]. 
2.5. In Vivo Biodistribution 
An in vivo pilot study was performed to assess the in vivo biodistribution of ACPP-B and CPP-B, 5 h 
post-injection, in a mouse model of myocardial infarction (MI). The conditions were similar to the earlier 
study with the MMP-2/9 sensitive probe 177Lu/125I-ACPP-2/9 [1] to facilitate comparison. We aimed to 
characterize the in vivo biodistribution of ACPP-B using a dual-isotope approach with 177Lu, labeled to 
the polycationic domain, and 125I, labeled to the polyanionic domain, as orthogonal radiolabels (see 
Supplemental Information for performed iodination procedures). Although iodination of ACPP-B 
resulted in efficient conjugation of 125I to the peptide (Figure S5), the oxidative conditions, needed for 
activation of 125I, resulted in disulfide formation between cysteine residues, resulting in ACPP-B peptide 
dimers (Figure S6). An alternative approach, activating 125I in iodination tubes prior to conjugation to 
ACPP-B in a normal tube resulted in ~60% labeling. Unfortunately, a >95% radiochemical purity could 
not be achieved by solid phase extraction (Figure S5), and desalting strategies to remove 125I could not 
be applied due to the low molecular weight of the peptide. Therefore, re-design of the ACPP-B peptide 
structure, to prevent side-reactions during iodination, may enable dual-isotope studies. Hereto, the 
cysteine residue can be acetylated, but oxidation of the sulfur atom may still occur. Furthermore, this 
conversion results in a more hydrophobic residue that may impact the MT1-MMP sensitivity of the 
probe. Substitution of the cysteine by a serine residue will possibly be a more attractive option. 
Alternatively, iodine may be introduced specifically to the N-terminus via coupling of a 125I-SHPP 
moiety (following a similar approach as proposed for iodination of ACPP-C (Figure 1)). 
Here, a single isotope labeled probe 177Lu-ACPP-B was employed in a pilot in vivo study. The 
biodistribution studies in MI-mice, 10 days after induction of a myocardial infarction, revealed a 
significantly higher uptake of 177Lu radiolabeled ACPP-B (p < 0.001) in infarcted regions of the heart 
compared to remote myocardium (Table 1). Evaluation of ACPP-2/9 in the same mouse model earlier 
demonstrated a higher uptake of ACPP-2/9 in the infarcted heart compared to ACPP-B, but also in other 
tissues such as remote myocardium, muscle, lung, spleen, and liver, while the accumulation of ACPP-2/9 in 
kidney was lower compared to ACPP-B (Table 1). Furthermore, the studies exploring ACPP-2/9,  
non-ACPP-2/9, and CPP-2/9, revealed that the activated domain of the ACPP-2/9 imaging probe is 
efficiently taken up by the liver, while the intact probe is accumulated in the kidneys [1,24,25]. These 
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experiments showed that a significant fraction of ACPP-2/9 was activated in the vasculature and 
subsequently taken up by the liver with a kidney-to-liver ratio of 2.1 (Table 1). Importantly, ACPP-B 
mainly accumulated in the kidneys with a kidney-to-liver ratio of 14.9, and this suggests a diminished 
activation of ACPP-B in the vasculature. Notably, ACPP-B showed a similar blood kinetic profile 
(Figure 6) as ACPP-2/9 [1], with a blood half-life of ~24 min. The calculated volume-of-distribution for 
ACPP-B is 0.3 L/kg, which is also in the same range as for ACPP-2/9, and indicates that the probe is 
rapidly distributed throughout the extracellular extravascular space [29]. These results indicate that the 
differences between ACPP-2/9 and ACPP-B activation in the vasculature cannot be attributed to 
difference in blood kinetics, but are most likely the result of the difference in sensitivity for circulating 
MMPs. We demonstrated that ACPP-2/9 is sensitive towards the soluble proteases MMP-2 and  
MMP-9 [24], while ACPP-B showed in vitro sensitivity towards MMP-2, but not for MMP-9 (Figure 4). 
Table 1. Biodistribution results of 10 nmol 177Lu-ACPP-B, and 177Lu-ACPP-2/9 5 h  
post-injection in MI-mice. The data are mean %ID/g ± SD. Data for 177Lu-ACPP-2/9 are 
reprinted from [1]. 
 
177Lu-ACPP-B 
(n = 5) 
177Lu-ACPP-2/9  
(n = 3) 
Blood 0.08 ± 0.03 0.09 ± 0.03 
Heart, infarct 0.75 ± 0.15 3.60 ± 0.68 
Heart, remote 0.11 ± 0.02 0.35 ± 0.13 
Muscle 0.09 ± 0.07 0.48 ± 0.14 
Lung 0.38 ± 0.09 1.09 ± 0.30 
Spleen 0.77 ± 0.13 2.72 ± 1.48 
Liver 6.76 ± 0.91 28.5 ± 5.33 
Kidney 100.4 ± 13.0 59.9 ± 8.10 
Fat 0.43 ± 0.28 0.33 ± 0.08 
Thigh bone 1.92 ± 0.73 2.47 ± 1.02 
Brain 0.01 ± 0.01 0.02 ± 0.01 
 
Figure 6. Blood kinetics of 177Lu-ACPP-B in MI-mice (n = 3). The data are mean %ID/g ± SD 
and fitted to the 2-phase exponential decay function Y = span1 × exp(−K1 × X) + span2 × 
exp(−K2 × X) + Plateau. Span1 = 2.61%ID/g, K1 = 1.99 min−1, Span2 = 7.35%ID/g,  
K2 = 27.1 min−1. 
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Acute MI is characterized by an increased vascular permeability and increased interstitial space [30]. 
Therefore, the increased uptake of 177Lu-ACPP-B in the infarcted region compared to remote region 
does not necessarily warrant MT1-MMP mediated probe activation but can also be associated with  
non-specific leakage of the ACPP-B probe into the infarcted myocardial interstitial space. We therefore 
compared the infarct-to-remote ratio for 177Lu-ACPP-B and the positive control 177Lu-CPP-B (Supplemental 
Table 1) and found an increased ratio for ACPP-B (Figure 7), suggesting that infarct uptake of  
177Lu-ACPP-B is associated with tissue-specific activation. However, the difference was not statistically 
significant (p = 0.17) due to the relatively high variation for ACPP-B. The high variation is most likely 
related to the relatively high biological variation typically observed for the MI-model [31]. This  
MI-mouse model is known for its relatively high mortality and more importantly large variation in 
myocardial ischemia and infarct size. We therefore believe that high variation in biodistribution data is 
caused by the relatively high biological variation (e.g., MMP expression) per MI-mouse as a result of 
the variability in the surgical intervention. Extended biodistribution studies and, in particular, dual-isotope 
studies would be valuable to verify if ACPP-B probe activation occurs in vivo and to specify the 
localization, with a special interest in infarcted and remote areas of the heart. Such studies could  
further address the question if ACPP-B will out-perform ACPP-2/9 in terms of specific targeting of 
infarcted myocardium. 
 
Figure 7. Infarct-to-remote ratio for 177Lu-ACPP-B and 177Lu-CPP-B. The data are mean ± SD.  
3. Experimental Section 
3.1. Materials 
All reagents and solvents were obtained from commercial sources (Sigma-Aldrich, St. Louis, MO, 
USA, and Biosolve, Lexington, MA, USA) and used without further purification.  
9-fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids and Rink amide resin were purchased 
from either Novabiochem (Merck, Kenilworth, NJ, USA) or Iris Biotech. DOTA succinimidyl ester was 
obtained from Macrocyclics. Human recombinant enzymes were purchased from Calbiochem (Merck), 
Sigma-Aldrich, or R&D Systems (Minneapolis, MN, USA). The enzymes were activated according to 
vendors’ protocols if needed. 
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3.2. Probe Synthesis 
Peptides Ac-y-e9-X-CPKESCNLFVLKD-X-r9-dab(ivDde)-resin, Ac-y-e9-X-CRPAHLRDSG-X-r9-
k(ivDde)-resin, and Fmoc-e9-X-PLACmobWAR-X-r8-k(Mtt)-resin were synthesized on an automatic 
synthesizer (Prelude, Protein Technologies Inc., Tucson, AZ, USA ) by Fmoc solid-phase peptide 
synthesis (SPPS) using Chemmatrix rink amide resin (0.1 mmol), HBTU as the activating reagent, and 
N,N-Diisopropylethyl amine (DIPEA) as base. D-amino acids are denoted in lower case. X and Cmob 
represents 5-amino-3-oxapentanoic acid and 4-methoxybenzyl-L-cysteine, respectively. The ivDde 
protecting group was selectively removed by incubating Ac-y-e9-X-CPKESCNLFVLKD-X-r9-
dab(ivDde)-resin, and Ac-y-e9-X-CRPAHLRDSG-X-r9-k(ivDde)-resin with 5.0% v/v hydrazine-
monohydrate in DMF for 10 × 3 min. The Mtt protecting group was selectively removed by incubating 
Fmoc-e9-X-PLACmobWAR-X-r8-k(Mtt)-resin with 1.8% v/v trifluoroacetic acid (TFA) in 
dichloromethane with 2.0% v/v tri-isopropylsilane (TIS) as scavenger for 10 × 3 min. DOTA 
succinimidyl ester (4.0 equiv) in NMP was added to the peptide resins and was reacted for 1 h in the 
presence of DIPEA. After Fmoc removal, the peptides were cleaved from the resin by a mixture of 90.5% 
v/v trifluoroacetic acid (TFA), 2.0% v/v 1,2-ethanediol (EDT), 5.0% v/v tri-isopropyl silane (TIS), and 
2.5% v/v MilliQ (Millipore, Billerica, MA, USA) water for 4 h, filtered, and precipitated in ice cold 
diethylether. The peptide pellets were dissolved in MilliQ water and purified by preparative reversed-
phase high pressure liquid chromatography (RP-HPLC) using an Agilent 1200 apparatus, equipped with 
a C18 Zorbax column (150 × 21.2 mm, particle size 5.0 µm). The elution gradient was set from 5% to 
30% of buffer B (0.1% TFA in acetonitrile) over 100 min, where buffer A was 0.1% TFA in MilliQ 
(Millipore) water. The UV wavelength was preset at 210 and 254 nm. All peptides structures were 
analyzed by LC-MS on an Agilent 1200 apparatus, equipped with a C18 Eclipse plus-column (100 × 2.1 
mm, particle size 3.5 µm) and an electrospray mass spectrometer (Agilent Technologies 6210, Time-of-
Flight LC/MS, Santa Clara, CA, USA) Peptide Ac-y-e9-X-CPKESCNLFVLKD-X-r9-dab(DOTA)-NH2 
was cyclized at 50 rpm in 15% v/v DMSO, 10% v/v acetonitrile, and 75% v/v MilliQ water for 3 days, 
purified by RP-HPLC, and analyzed by LC-MS. The positive control of Ac-y-e9-X-CRPAHLRDSG-X-
r9-k(DOTA)-NH2 was obtained by incubating 50% of this peptide (1.0 mM) with 60 nM MT1-MMP in 
a mixture of 50 mM Tris, 200 mM NaCl, 10 mM CaCl2 and 10 µM ZnCl2 at pH 7.5 at 700 rpm and  
37 °C for 24 h, after which the polycationic domain was isolated by RP-HPLC, and analyzed by LC-
MS. To test SHPP introduction, 50% of peptide e9-X-PLACmobWAR-X-r8-k(DOTA)-NH2 was reacted 
with 3-(4-hydroxyphenyl)propionic acid (SHPP) N-hydroxysuccinimide ester (10 equiv) in DMF in the 
presence of DIPEA for 6 h, after which the peptide was purified by RP-HPLC, and analyzed by LC-MS. 
Found masses: 4953.4 Da for Ac-y-e9-X-CPKESCNLFVLKD-X-r9-dab(DOTA)-NH2 (Calcd.  
4953.4 Da), 4951.4 Da for Ac-y-e9-X-C*PKESC*NLFVLKD-X-r9-dab(DOTA)-NH2 (ACPP-A, Calcd. 
4951.4 Da), 4597.3 Da for Ac-y-e9-X-CRPAHLRDSG-X-r9-k(DOTA)-NH2 (ACPP-B, Calcd.  
4597.3 Da), 2565.5 Da for LRDSG-X-r9-k(DOTA)-NH2 (CPP-B, Calcd. 2565.5 Da), 4061.2 Da for  
e9-X-PLACmobWAR-X-r8-k(DOTA)-NH2 (Calcd. 4061.1 Da), and 4209.1 Da for SHPP-e9-X-
PLACmobWAR-X-r8-k(DOTA)-NH2 (ACPP-C, Calcd. 4209.1 Da). 
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3.3. MT1-MMP Sensitivity 
ACPP-A, ACPP-B, and ACPP-C (0.1 mM) were incubated with 15 nM MT1-MMP in a mixture of 
50 mM Tris, 200 mM NaCl, 10 mM CaCl2 and 10 µM ZnCl2 at pH 7.5 at 700 rpm and 37 °C. After 1 h, 
the enzyme was quenched by the addition of TFA (10% v/v), and the reaction mixture was analyzed  
by LC-MS. 
3.4. Enzyme Assay 
ACPP-B and ACPP-C were incubated in triplicate with 20 nM of either human recombinant MMP-1, 
MMP-2, MMP-3, MMP-7, MMP-9, MT1-MMP, MT2-MMP, MT3-MMP, ADAM-17, thrombin, 
plasmin, or urokinase in a mixture of 50 mM Tris, 200 mM NaCl, 10 mM CaCl2 and 10 µM ZnCl2 at 
pH 7.5 at 700 rpm and 37 °C. After 1 h, the enzymes were quenched by the addition of TFA (10% v/v) 
and the reaction mixtures were analyzed by LC-MS. The formation of the activated cell penetrating 
peptide domain was monitored and compared to a 100% cleaved reference sample. 
3.4.1. Radiolabeling 
For in vitro cell assay: 177LuCl3 (PerkinElmer, Waltham, MA, USA) in 0.05 M HCl (2.0 µL, 4.0 MBq) 
was mixed with ACPP-B, non-ACPP, CPP-B, or CPP in MilliQ water (2.69–4.60 µL, 20.0 nmol), and 
metal-free 0.9% NaCl (final volume 100 µL) for 20 min, at 600 rpm and 90 °C. 
For in vivo studies: 177LuCl3 in 0.05 M HCl (6.0 µL, 18.0 MBq) was mixed with ACPP-B or CPP-B 
in MilliQ water (10.4 µL, 45 nmol), and metal-free 0.9% NaCl (433.6 µL) for 20 min, at 600 rpm and 
90 °C. The 177Lu labeling yields were determined by radio-TLC, using iTLC-SG strips (Pall, Port 
Washington, NY, USA) eluted with 200 mM EDTA in 0.9% NaCl, imaged on a phosphor imager  
(FLA-7000, Fujifilm, Tokyo, Japan) and quantified with AIDA Image Analyzer software. Analytical 
radio-HPLC was carried out on an Agilent 1100 system equipped with a C18 Eclipse XBD-column  
(150 × 4.6 mm, particle size 5 µm) and a Gabi radioactive detector (Raytest). The radiochemical purities 
were 95% or higher, and typically at least 98%. ACPP-2/9 was labeled with 177Lu as previously  
described [1]. 
3.4.2. Cell Culture 
HT-1080 fibrosarcoma cells acquired from the American Type Culture Collection (ATCC) were 
maintained under standard culture conditions in Eagle’s Minimal Essential Medium (MEM) 
supplemented with 10% heat inactivated fetal bovine serum (Gibco, Waltham, MA, USA), penicillin 
(100 U/mL), streptomycin (100 µg/mL), and 2 mM Glutamax (Gibco). 
3.4.3. In Vitro Cell Incubation with Radiolabeled ACPP Probes 
177Lu-ACPP-B (50 µM) was activated prior to cell incubation with recombinant human MT1-MMP 
(100 nM) for 2 h in 50 mM Tris, 200 mM NaCl, 10 mM CaCl2 and 10 µM ZnCl2 at pH 7.5, as was 
assessed by RP-HPLC. HT-1080 cells were cultured in 12-well plates. At 95% confluency, cells were 
washed with Dulbecco’s PBS (Gibco) and subsequently incubated in triplicate with 1.25 µM  
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177Lu-non-ACPP, 1.25 µM uncleaved 177Lu-ACPP-B, 1.25 µM pre-cleaved 177Lu-ACPP-B, and 1.25 µM 
177Lu-CPP-B (0.25 MBq 177Lu) respectively in serum-free medium (1 mL). After 3 h of incubation, cells 
were washed 3× with Dulbecco’s PBS, and treated with trypsin (0.25% w/v trypsin-EDTA (Gibco)) to 
digest and remove surface-bound peptide [32] and harvest the cells. The trypsin activity was inhibited 
by addition of MEM, after which the cells were isolated by centrifugation (1000 rpm, 5 min, RT). Cell 
pellets and all wash fractions were analyzed for 177Lu radioactivity (115–270 keV) by a γ-counter 
(Wizard 1480, PerkinElmer). 
MMP blocking study: HT-1080 cells were cultured in 12-well plates. At 95% confluency, cells were 
washed with Dulbecco’s PBS (Gibco) and subsequently incubated (n = 4) with 1.25 µM 177Lu-non-ACPP, 
1.25 µM 177Lu-ACPP-B, and 1.25 µM pre-cleaved 177Lu-ACPP-B + 50 µM GM6001, respectively in 
serum-free medium (1 mL). After 4 h of incubation, cells were washed 3× with Dulbecco’s PBS and 
harvested by trypsination (0.25% w/v trypsin-EDTA (Gibco)). The trypsin activity was inhibited by 
addition of MEM, after which the cells were isolated by centrifugation (1000 rpm, 5 min, RT). Cell 
pellets and all wash fractions were analyzed for 177Lu radioactivity (115–270 keV) by a γ-counter. 
3.4.4. Animal Studies 
All animal procedures were approved by the ethical review committee of the Maastricht University 
Hospital (The Netherlands), and were performed according to the principles of laboratory animal care 
(NIH publication 85–23, revised 1985) [33], and the Dutch national law “Wet op Dierproeven”  
(Stb 1985, 336). Male Swiss mice (body weight >25 g, Charles River Labs) were housed in an enriched 
environment under standard conditions: 21–23 °C, 50%–60% humidity, and 12 h-lightdark-cycles for 
>1 week. Food and water were freely available. 
3.4.5. Mouse Model of Myocardial Infarction (MI) 
MI was induced by permanent ligation of the left anterior descending coronary artery (LAD) using 
published procedures [34]. In short, animals were subcutaneously injected with buprenorphine (0.1 mg/kg) 
and 30 min later anesthetized with isoflurane. Animals were intubated and ventilated with 100% oxygen 
with a rodent respirator. After left thoracotomy between ribs four and five, the LAD was ligated with a 
6–0 prolene suture. The chest and skin were closed with 5–0 silk sutures. The animal’s temperature was 
continuously measured rectally and maintained at 36.5–37.5 °C during surgery. After surgery, animals 
were allowed to recover at 30 °C overnight. 
3.4.6. Blood Kinetics and Biodistribution 
Biodistribution experiments were performed on MI-mice (n = 5 per probe) by i.v.-injection of  
177Lu-ACPP-B (10 nmol/100 µL, ca. 4.0 MBq 177Lu), or 177Lu-CPP-B (10 nmol/100 µL, ca. 4.0 MBq 
177Lu). For animals injected with 177Lu-ACPP-B, blood samples were withdrawn from the vena saphena 
at selected time points (3, 9, 27, and 81 min), weighed, and diluted to 1 mL with MilliQ water. The mice 
were anesthetized with isoflurane 5 h after i.v.-injection, subjected to 2% (w/v) Evans Blue i.v.-injection 
(50 mg/kg) and sacrificed 2 min later by cervical dislocation. Organs and tissues of interest were 
harvested and weighed. The hearts were cooled to 4 °C, cut in 1 mm slices from apex to base. Infarct, 
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border, and remote areas were isolated based on Evans Blue staining. The 177Lu radioactivity of all 
samples was measured in a γ-counter (Wizard 1480; PerkinElmer) along with standards to determine the 
injected dose per gram (%ID/g). The energy window was set to 155–380 keV. The average probe 
concentration at time 0 (C0) was calculated by fitting the blood clearance data to the 2-phase exponential 
decay function Y = span1 × exp(−K1 × X) + span2 × exp(−K2 × X) + Plateau using GraphPad Prism. The 
area under the curve (AUC) was determined and the blood half-life, the time point at which the AUC 
reaches 50% of the total AUC, was subsequently derived using MatLab. The average volume of 
distribution was calculated using the formula VD = dose/(mean body weight × C0) [L/kg]. 
4. Conclusions 
We have successfully developed a series of activatable cell penetrating peptides (ACPP) sensitive to 
MT1-MMP. The most potent ACPP analog, ACPP-B, was selected by MT1-MMP sensitivity and 
enzyme specificity assays. In in vitro cell assays, radiolabeled ACPP-B showed efficient cellular uptake 
upon activation. Furthermore, the level of in vivo background activation in the vasculature was decreased 
compared to ACPP-2/9, an earlier well-studied MMP-2/9 ACPP probe, while an increased uptake in 
infarcted heart tissue was observed compared to remote heart tissue, which warrants future research into 
the in vivo biodistribution and behavior of ACPP-B. 
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Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/07/12076/s1. 
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